VNRX: Strong IP, new products, and global partnerships drive licensing and clinical adoption in 2026
Recent milestones include a $5M milestone opportunity, new product launches, and expansion into non-sepsis disease areas. The company leverages a strong IP portfolio, asset-light model, and global partnerships, with multiple licensing deals and clinical adoption targeted for 2026.Original document…